title: A Randomized Trial of Creatine-kinase Leak After Rosuvastatin in Elective Percutaneous Coronary Intervention (CLEAR-PCI).
abstract: OBJECTIVE
  To determine the impact of percutaneous coronary intervention (PCI) performed at the same time of the peak concentration of rosuvastatin to reduce periprocedural myocardial infarction (PMI).
  
  
  BACKGROUND
  Prior studies suggest that a high dose of statin before PCI reduce periprocedural myocardial infarction. However, there is no information regarding the elective PCI performed at the time of the peak of statin concentration to reduce PMI.
  
  
  METHODS
  From 2001 to 2013, at a single center in Brazil we enrolled 544 patients who underwent elective PCI and after exclusions for baseline biases in clinical and angiographic characteristics, yielding 528 patients, we prospectively randomly assigned them to either a high loading dose of Rosuvastatin before PCI (n = 264) or standard treatment (n = 264). After exclusions for biases in procedural characteristics a total of 487 patients underwent to end points analysis. The primary outcome was the incidence of MB fraction of creatine kinase (CK-MB) greater than three times the upper limit of normal.
  
  
  RESULTS
  The primary end point occurred in 7.6% in the rosuvastatin and 4.8% in the control group (P = 0.200). There was a higher incidence in elevation of CK-MB than normal baseline in the rosuvastatin (67.1% vs 59.2%, P = 0.701). There was no difference in major adverse event (0% in the rosuvastatin group vs 0.8% in control).
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, Interventional Cardiology, Sao Paulo, Brazil.
authors.forename: Kleber B A
authors.initials: KB
authors.lastname: Martins
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, Interventional Cardiology, Sao Paulo, Brazil.
authors.forename: Luiz A P
authors.initials: LA
authors.lastname: Mattos
authors.affiliation: Instituto Dante Pazzanese, Interventional Cardiology, Sao Paulo, Brazil.
authors.forename: Amanda G M R
authors.initials: AG
authors.lastname: Sousa
authors.affiliation: Instituto Dante Pazzanese, Interventional Cardiology, Sao Paulo, Brazil.
authors.forename: J Eduardo M R
authors.initials: JE
authors.lastname: Sousa
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, Sao Paolo, Brazil.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Abzaid
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, Interventional Cardiology, Sao Paulo, Brazil.
authors.forename: Fausto
authors.initials: F
authors.lastname: Feres
authors.affiliation: Instituto Dante Pazzanese, Interventional Cardiology, Sao Paulo, Brazil.
authors.forename: José C
authors.initials: JC
authors.lastname: de Ribamar
authors.affiliation: Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil.
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Staico
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, Interventional Cardiology, Sao Paulo, Brazil.
authors.forename: Ricardo A
authors.initials: RA
authors.lastname: Costa
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, Interventional Cardiology, Sao Paulo, Brazil.
authors.forename: Aurea J
authors.initials: AJ
authors.lastname: Chaves
mesh_terms: D015415:Biomarkers / Q000097:blood; D003324:Coronary Artery Disease / Q000628:therapy*; D052279:Creatine Kinase, MB Form / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D017558:Elective Surgical Procedures; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control; D062645:Percutaneous Coronary Intervention; D011446:Prospective Studies; D000068718:Rosuvastatin Calcium / Q000008:administration & dosage*
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000068718:Rosuvastatin Calcium; D052279:Creatine Kinase, MB Form